.
MergerLinks Header Logo

Announced

Completed

ArchiMed completed an investment in PlasmidFactory.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Minority

Single Bidder

Biotechnology

gene therapy

Private

Germany

Completed

Acquisition

Friendly

cell therapy

Private Equity

Cross Border

Synopsis

Edit

ArchiMed, a private equity firm, completed an investment in PlasmidFactory, a gene and cell therapy specialist. Financial terms were not disclosed. “ArchiMed will act as our key catalyst for rapid and efficient expansion in a highly complex domain that few generalist investors, or a few healthcare investors, understand.” Schleef and his management team will remain in place, with the former rolling over a substantial portion of his proceeds in the group," Martin Schleef, PlasmidFactory Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US